Replies to post #120798 on Biotech Values

[genisi]

It was Wyeth/Elan that did the “nonlinear” reanalysis and presented the data at the ICAD meetings in July 2008:

http://www.slideshare.net/finance12/wyeth-phase-2-clinical-trial-of-bapineuzumab-icad-july-2008